No FDA-approved stem-cell therapy exists for SMA. Two proven disease-modifying therapies are FDA-approved — nusinersen (slows progression) and onasemnogene abeparvovec gene therapy (durable motor benefit, especially in infants). Stem-cell therapies are investigational and lack comparable evidence; claims of approval or equivalence are false.
Spinal Muscular Atrophy is a genetic neuromuscular disorder caused by SMN1 mutations, leading to insufficient survival motor neuron protein and progressive motor-neuron loss and muscle atrophy. Stem-cell research explores neurogenic cells to support or replace motor neurons and placental mesenchymal stem cells to secrete neuroprotective factors and reduce neuroinflammation. Because SMA is genetic, cellular approaches that do not correct the underlying SMN deficiency may offer limited long-term benefit. This distinguishes SMA from acquired disorders, and helps explain why approved gene-targeted therapies dominate care. Trials are very few; reported outcomes focus on motor-function stabilisation rather than recovery.
Am I a candidate? → · Spinal Muscular Atrophy: full overview → · Spinal Muscular Atrophy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită